Acute myeloid leukemia, or AML, is a type of blood cancer that starts in the bone marrow and rapidly moves to the bloodstream. It can spread to other parts of the body, including the lymph nodes, liver, and nervous system. AML, which accounts for about 1% of all cancers, could result in 11,090 deaths this year, according to the American Cancer Society.
The company we are profiling today is a late-stage clinical biopharmaceutical company developing a WT1-targeting cancer immunotherapeutic for acute myeloid leukemia - SELLAS Life Sciences Group Inc. (SLS).
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.